Israel News App

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars – Biocon

Written by

admin

in

  1. Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars  Biocon
  2. FDA Approves 2 Biosimilars for Osteoporosis and Cancer-Related Bone Disease  OncLive
  3. Hikma And Richter Receive Denosumab Nods In US  

Continue Reading